Financial terms of the agreement, which will dismiss the lawsuit, weren't announced. But Mylan Pharmaceuticals will get the go-ahead to launch a generic 200mg version of Comtan after April 1, 2013.

CHICAGO (Reuters) - Drugs used to treat Parkinson's disease show promise as a new way to stem the rise of drug-resistant forms of tuberculosis, U.S. researchers said on Thursday.

These entacapone-containing products (Comtan and Stalevo) have been shown to be effective in treating symptoms of PD, such as muscle stiffness, tremors, spasms, and poor muscle control.

Both Stalevo and Comtan are used to treat symptoms of Parkinson's disease. The data being reviewed are from a long-term clinical trial called Stalevo Reduction in Dyskinesia Evaluation - Parkinson ...

Orion Corporation has filed a patent infringement lawsuit in the United States to enforce Orion's U.S. patent No. 5,446,194 covering Comtan ® against Mylan Pharmaceuticals Inc. (Mylan).

Alembic has received the Food and Drug Administration’s permission for entacapone tablets in a dosage strength of 200 mg. The product is the generic of Orion’s Comtan. The drug is indicated as ...

HELSINKI, Nov 12 (Reuters) - Finnish drug firm Orion <ORNBV.HE> said on Wednesday it has filed a patent infringement lawsuit in the United States to protect its key drug Comtan, used for treatment ...

Under the terms of the settlement agreement, Sun Pharma will be able to launch generic versions of 25/100/200 mg and 37.5/150/200 mg strengths of Stalevo tablets in the US on 1 April 2012. In ...

It is estimated that 154,000 patients were dispensed a prescription for Stalevo from its approval in June 2003 through October 2009. At this time, FDA's review of the potential cardiovascular risk ...

Comtan contains entacapone, a COMT enzyme inhibiting agent originated and patented by Orion. The lawsuit was filed by Orion in the U.S. in 2011.

Wockhardt has got USFDA nod for generic version of Comtan, reports CNBC-TV18. The share touched a 52-week high of Rs 1,325. At 09:24 hrs the share was quoting at Rs 1,318.00, up Rs 19.35, or 1.49%.

The firm said it is currently evaluating its legal options to protect its rights, noting that under the US system, if a patent owner brings a lawsuit against an ANDA applicant within a certain time ...